In response to emerging concerns that environmental chemicals may have adverse effects on human health by altering the function of the endocrine system, the Food Quality Protection Act mandated that the U.S. Environmental Protection Agency (U.S. EPA) develop and implement an Endocrine Disruptor Screening Program (EDSP; U.S. EPA, 2006) . Toward this end, the U.S. EPA is evaluating a number of in vitro and in vivo assays designed to detect chemicals that can interact with the estrogen, androgen, and thyroid systems in human, fish, and wildlife (U.S. EPA, 2006) . Following a validation process, some of these assays will be selected for use in a Tier I screening battery.
The estrogen receptor (ER)-competitive binding assay is one of the methods currently being validated. This in vitro assay was recommended by the Endocrine Disruptor Screening and Testing Advisory Committee, a federal advisory group charged with assisting the U.S. EPA in development of a scientifically defensible EDSP (U.S. EPA, 1998a) . The assay can be used to determine the relative binding affinities (RBAs) of environmental chemicals for the ER, by comparison with the endogenous hormone, estradiol (E 2 ). The assay measures the ability of radiolabeled E 2 to bind with rat uterine cytosolic (RUC) ER in the presence of increasing concentrations of a test chemical (Clark and Gorski, 1969; ICCVAM, NIEATM, 2003a; Markaverich et al., 1983; U.S. EPA, 1998b) . Environmental chemicals that compete with estrogen for binding to ER have the potential to either induce (agonist) or block (antagonist) estrogen-dependent transcriptional activity since ER association is the initial step in a series of events that culminate in multiple estrogen-dependent physiological responses (Tsai and O'Malley, 1994; Brzozowski et al., 1997) . Using this assay as a screening tool can provide a fairly rapid and inexpensive method for identifying likely endocrine disrupting substances (ICCVAM, NIEATM, 2003b; Laws et al., 2006) .
Examples of the biological relevance and utility of this assay as a screening tool are evident from numerous publications where the ER-binding affinities of a variety of chemicals have been correlated with estrogenic or antiestrogenic physiological responses after in vivo exposures. Chemicals such as 4-tertoctylphenol, 4-nonylphenol, and bisphenol A, that have been shown to stimulate estrogenic activity in vivo, also inhibit the binding of E 2 in the ER-competitive binding assay (Ashby and Tinwell, 1998; Bicknell et al., 1995; Danzo, 1997; Hammond et al., 1979; Kuiper et al., 1998; Laws et al., 2000; Lee and Lee, 1996; Routledge and Sumpter, 1997; Takemura et al., 2005; White et al., 1994) . Elsby et al. (2000) compared the results from ER-binding and uterotrophic assays for 17-b-E 2 , and steroid analogues and found that the chemicals produced similar results in both assays. Similarly, Yamasaki et al. (2004) tested 14 chemicals in both assays, and their results demonstrated that the affinity of the chemicals in the ER-binding assay correlated well with their potency in the uterotrophic assay, although a few agonists had a very low receptor-binding affinity. On the other hand, while methoxychlor has a very low binding affinity for ER, its hydroxylated metabolite, 2,2,-bis(phydroxyphenyl)-1,1,1-trichlorethane, exhibits a moderate binding affinity for the ER and produces estrogenic responses in rats following administration in vivo (Bulger et al., 1978a,b; Gray et al., 1989; Kuiper et al., 1998) . Thus, while a direct correlation between the concentration of a chemical that can inhibit 50% of ER binding in vitro and a dose that will produce physiological effects in vivo may be obscured by pharmacokinetic factors (absorption, metabolism, tissue disposition, and elimination), the historical use of the ER-competitive binding assay clearly demonstrates its usefulness for initially identifying chemicals and/or their metabolites that can bind to the ER.
As part of the validation process for the RUC ER-competitive binding assay, the reliability of the assay must be demonstrated by its ability to produce similar results in multiple laboratories (ICCVAM, NICEATM, 2003b) . To meet this criterion, the U.S. EPA is currently evaluating assay performance in several contract laboratories by testing a set of chemicals with known ER-binding affinities (http://www.epa.gov/scipoly/oscpendo/ assayvalidation/status.htm). Data from these studies will be used to set the initial standards for performance criteria. In addition, guidance for data interpretation is needed to facilitate uniform, maximal use of the assay as a screening tool. Since the assay is intended to evaluate chemicals over a broad range of structural and physical properties as currently existing among chemicals under the purview of the U.S. EPA, it is expected that the data obtained from the assay will reflect a wide range of binding affinities for the ER. For example, some chemicals with high to moderate binding affinity will produce full competitive binding curves, while others with extremely low binding affinity will produce only partial curves. It is also likely that evaluation of some of the test chemicals will be limited by their lack of solubility in the aqueous assay buffer and/or their disruption of the biochemical kinetics of the binding assay itself. Thus, it is imperative that the validated protocol for the RUC ER-binding assay includes guidance for data interpretation to address these issues as well as to minimize the number of false-negative or -positive classifications of the test chemicals.
The study reported here was designed to evaluate the performance of the RUC ER-competitive binding assay when testing 50 chemicals selected from the high production volume inventory covered by the U.S. EPA's Toxic Substances Control Act. Chemicals were selected based upon unpublished data from ER-competitive binding assays previously conducted by Battelle Pacific Northwest Laboratories, Richland, WA (U.S. EPA Contract Number 68-W-99-033, Task 6). In the earlier experiments, some chemicals produced competitive binding curves that strongly indicated that they were true competitive inhibitors of ER binding. However, others produced only partial curves or irregular (nonsigmoid) binding curves. For this group of chemicals, additional secondary K i experiments were needed to understand fully whether or not these were true competitive inhibitors of ER binding (e.g., both the natural ligand and test chemical compete for the same site, Fig. 1 ). Thus, retesting this set of chemicals provided a unique opportunity to (1) compare the reproducibility of the RUC ER-competitive binding assay between two laboratories, (2) conduct the secondary K i experiments to demonstrate which chemicals were true competitive inhibitors of ER binding, (3) provide a data set of chemicals for which the ER-binding ability has been well characterized, and (4) develop guidance for appropriate data interpretation when using the assay as a screening tool. Therefore, for each chemical in this study that produced a curve suggestive of competitive binding to the ER, a secondary analysis was conducted to determine a K i and to distinguish which chemicals were true competitive inhibitors of ER binding.
MATERIALS AND METHODS
Chemical selection. The Chemical Abstract Service numbers and structures of the chemicals evaluated are shown in Figure 2 , and all are currently Table 1. under the U.S. EPA's purview. Chemicals were received from Battelle Pacific Northwest Laboratories and were identical to the specific lot used in their previous studies (Contract Number 68-W-99-033). Chemical purity ranged from 97 to 99%, and all chemicals were initially dissolved in 100% absolute ethanol (200 proof).
ER-competitive binding assay. RUC was used as the source of ER (containing both ER-a and -b) and was prepared using uteri from ovariectomized, adult Sprague-Dawley rats (Harlan Industries, Madison, WI). Following CO 2 euthanasia of the animals, the uteri were removed, trimmed of excess fat, and placed in ice-cold TEDG buffer (Tris 10mM, ethylene diamine tetraacetic acid 1.5mM, dithiothreitol 1mM, 10% glycerol, pH 7.4; ratio of 1 uterus/0.5 ml TEDG buffer). Tissues were homogenized with three to five bursts (approximately 5 s per burst; Polytron PT 35/10). The homogenate was transferred to precooled centrifuge tubes and centrifuged for 10 min at 2500 3 g at 4°C. The supernatant was transferred to precooled tubes and recentrifuged at 105,000 3 g for 60 min at 4°C. All supernatants were pooled, assayed for protein content (BCA Pierce), and frozen in 200 ll aliquots at ÿ 80°C.
Methods used for the RUC ER-competitive binding assay followed the protocol that is currently undergoing a multilaboratory validation under the Agency's EDSP program (http://iccvam.niehs.nih.gov/methods/endodocs/final/ erbndbrd/erbdappx/B5.pdf), with minor modification. Briefly, assays were conducted using RUC with a final protein concentration in each assay tube of 1.9-2.4 mg/ml and 0.33nM 3 H-17b-E 2 (Perkin Elmer NEN, NET-517, specific activity ¼ 170 Ci/mmol) in TEDG buffer. Each test chemical was evaluated over a concentration range of 0.1-100lM. Following an 18-h incubation at 4°C, bound and free ligands were separated by dextran-charcoal extraction, and bound radioligand was quantified by scintillation counting. Nonspecific binding was assessed by adding 200nM radioinert E 2 (Sigma E-9875, St Louis, MI). Specific binding was calculated by subtracting nonspecific binding from total binding. For each chemical, the assay was replicated on a second separate day. A full competitive binding curve using 17-b-E 2 (0.002-100nM) was included as a positive control for each daily assay.
Data were analyzed using a nonlinear regression program for fitting onesite competitive binding curves (GraphPad Prism, GraphPad Software, Inc. 2003, San Diego, CA), and estimates of IC 50 concentrations (e.g., the concentration of a test chemical required to inhibit 50% of the tracer maximal binding) were calculated. Competition by each test chemical that demonstrated an ability to reduce ER binding by 40% or greater was further evaluated with a K i experiment. Chemicals that did not inhibit ER binding by more than 20% at a concentration of 100lM were classified as nonbinders. K i experiments. K i values were experimentally determined by incubating increasing concentrations of 3 H-E 2 (0.05, 0.1, 0.2, 0.5, and 1.5nM) with ER in the presence of test chemical concentrations that bracketed the IC 50 (approximately 0.5, 1, and 2 3 IC 50 ). Using RUC as the source of ER (1.9-2.4 mg protein/ml), assays were allowed to incubate for 18 h at 4°C. Bound and free tracers were separated by dextran-charcoal, and ER-bound 3 H-E 2 was quantified by liquid scintillation counting. Double reciprocal plots (Lineweaver-Burk) were constructed of the bound versus total. A pattern of lines intersecting at the y-axis was considered characteristic of true competitive inhibition. Slopes obtained from each of the double reciprocal plots were replotted versus concentration of test chemical, and a K i was calculated from the negative intercept of the slope replot. K i experiments were replicated for chemicals demonstrating true competitive inhibition, and K i values are reported as mean ± SE (n ¼ 2).
RESULTS

ER-Competitive Binding Assays
The competitive binding assay measured the ability of 3 H-E 2 to bind with ER in the presence of increasing concentrations of a test chemical. Data from these assays provided an array of full and partial competitive binding curves. Results were grouped according to the ability to reduce radioligand binding. Chemicals in group A produced an almost complete displacement curve (e.g., maximal ER binding was inhibited by > 75%), group B displaced 50-74%, group C displaced 21-49%, group D displaced 0-20%, and group E produced irregular, nonsigmoidal curves. Chemicals in groups A, B, and E were tested in the secondary K i experiments. Further characterization of all but one chemical in group C was not possible due to solubility limitations. Chemicals in group D were designated as nonbinders when incubated at concentrations up to 100lM and were not tested further. Figure 3 presents examples of the variation in competitive binding curves observed among all the test chemicals. 17-b-E 2 was used as the positive control for all the assays. As shown in Figure 3a , increasing concentrations of radioinert E 2 over a range of 0.02-100nM produced a full sigmoid curve indicative of a chemical with a single, high-affinity binding site for the ER in accordance with the law of mass action (Motulsky and Christopoulos, 2003) . Specifically, tracer binding was reduced from 90 to 10% over an approximately 2 log unit increase in the nonradioactive E 2 concentration. Under these conditions, the IC 50 for E 2 was 0.52 ± 0.01nM and the K i was 0.77 ± 0.04nM, using the Cheng-Prusoff correction (Cheng and Prusoff, 1973) .
Group A consists of six chemicals that produced nearly complete competitive binding curves. A curve for 4-(1-methyl-1-phenylethyl)-phenol is shown as an example of this group of chemicals (Fig. 3a) . Twelve chemicals were included in group B and produced partial competitive binding curves at slightly more than 50% displacement (e.g., 4,4#,4$-ethane-1,1,1-triyltriphenol and phenyl(2,3,4-trihydrophenol)-methanone Figs. 3b and 3c). Examples of two chemicals that at concentrations up to 100lM produced curves with 21-49% displacement (group C) are shown in Figure 3c (5-chloro-2-(2,4-dichlorophenoxyl) phenol, 2,2-dimethoxy-1,2-diphenylethanone). Solubility limitations for eight of the nine chemicals in this group prevented further testing with the secondary K i assay. Another 18 chemicals did not inhibit ER binding more than 20% at concentrations up to 100lM (group D) and were classified as nonbinders (Fig. 3d , 4,4#-propane-2,2-diylbis-(2-tert-butylphenol)).
Examples of the four chemicals (group E) that produced nonsigmoidal binding curves are shown in Figures 3c and 3d . N,N-dimethyl-N-(3-trimethoxysilyl)propyl-octadecan-1-aminium chloride and N,N,N-trimethyl-octadecan-1-aminium chloride (Fig. 3d) were among the three chemicals for which the maximal binding of 3 H-E 2 dropped dramatically over a single log increase in concentration of either of these chemicals. 4-Dodecylbenzene-sulfonic acid produced a U-shaped curve as the concentrations were increased from 1.0 to 100lM (Fig. 3c) . The shapes of all these curves suggested that the biochemical stability of the binding assay may have been compromised, and all these chemicals warranted further testing by secondary K i experiments.
ESTROGEN RECEPTOR-BINDING AFFINITY K i Experiments K i concentrations (means ± SEM, n ¼ 2) for the 17 chemicals that exhibited true competitive inhibition are shown in Table 1 . Five of six chemicals in group A and 11 of 12 chemicals in group B were confirmed to be true ER-competitive binders by reanalysis of competitive binding properties using a series of Lineweaver-Burk plots. Data are shown in Figure 4 for (1) 4-(1-methyl-1-phenylethyl)-phenol, (2) 4,4#4$-ethane-1,1,1-triyltriphenol, (3) phenyl(2,3,4-trihydroxyphenyl)-methanone, and (4) 2,2-dimethoxy-1,2-diphenylethanone. None of the chemicals in these groups exhibited an ability to bind to ER at concentrations approximating E 2 itself (K i ¼ 0.77nM). K i concentrations for this group of chemicals ranged from 0.5 to 373lM or by 1000-850,000 times the K i for E 2 .
All the four chemicals that produced nonsigmoid competitive binding curves also failed to exhibit true competitive inhibition when evaluated in the secondary K i experiments. For all chemicals where the competitive binding curve dropped dramatically over a single log increase in concentration, the follow-up K i experiment demonstrated that each was not a true competitive inhibitor (N,N,N-trimethyloctadecan-1-aminium chloride [ Fig. 5a ], octanal, and N,N-dimethyl-N-(3-trimethoxysilyl)propyl-octadecan-1-aminium chloride [ Fig. 5b]) . In these cases, the reduction in the maximal binding of tracer was likely due to an interference with the assay conditions by denaturing the ER, altering pH, and disrupting the receptor conformation such that it was no longer capable of binding E 2 . 4-Dodecylbenzenesulfonic acid, a chemical that produced a U-shaped binding curve, was also confirmed to be a nonbinder (Fig. 5c) .
Finally, there were other chemicals for which the secondary K i experiments facilitated the proper classification as ER binders or nonbinders. N,N-dimethyltetradecan-1-amine (112-03-8) and N,N-dimethyl-N-(3-(trimethoxylsilyl) propyl)octadecan-1-aminium chloride (27668-52-6) demonstrate binding curves that dropped rapidly over a single log unit. Secondary analysis showed that these chemicals were disrupting the binding assay (Figs. 5a and 5b) . 4,4#-Propane-2,2-diylbis(2-tert-butylphenol) (79-96-9, group D) demonstrates the group of nonbinders. -60-5 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12, 12,12- produced a nearly complete competitive binding curve, and sodium-5-chloro-2-(4-chloro-2-(((3,4-dichlorophenyl)-carbamoyl)-amino)phenoxy) benzene sulfonate hydrate and 5-chloro-2-(2,4-dichlorophenoxyl)phenol produced partial competitive binding curves similar to other chemicals that were ER binders. However, the secondary binding assays indicated that these chemicals were nonbinders (Figs. 3c and 5d; 5-chloro-2-(2,4-dichlorophenoxyl)phenol exemplifies data from these chemicals). Of the chemicals in group C, further testing by a K i experiment for eight of nine was not possible because the limit of solubility of each was well above the IC 50 . These chemicals are currently being reevaluated using DMSO rather than ethanol as the initial stock solvent.
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Comparison of Data Interpretations Using Only ER-Competitive Binding Curves as Opposed to the K i Experiments
Results from the present competitive binding assays were compared with data obtained from initial tests at Battelle Pacific Northwest Laboratories. In the earlier study, a chemical was categorized as an ER binder if it displaced the maximal binding of 3 H-E 2 by 50% or greater. The assay was considered inconclusive for chemicals that displaced 20-49%, while chemicals whose inhibition dropped rapidly over a single log concentration unit, or that displaced < 20%, were classified as nonbinders. Comparison of results from the two laboratories indicated that there was 94.4% concordance among the 17 chemicals that were designated in this study as true competitive binders using the K i experiments. Two chemicals not detected in the earlier study were classified as ''inconclusive'' in the present assay when based solely on the competitive binding assay.
Use of the K i experiments was most helpful in differentiating between the chemicals with partial binding curves of up to 50% displacement as well as for those that presented nonsigmoidal curves. For example, both 5-chloro-2-(2,4-dichlorophenoxyl)-phenol and 2,2-dimethoxyl-1,2-diphenylethanone (Fig. 3c ) produced similar competitive binding curves with slightly less than 50% displacement of maximal binding. However, only the latter was actually a true competitive binder. All K i experiments for the chemicals with the rapid drop in binding over a single log unit were demonstrated to be nonbinders using the K i experiments. Finally, there were two chemicals in this study that would have been incorrectly designated as an ER binder if evaluated solely with competitive binding curves (N,N-dimethyltetradecan-1-amine and sodium-5-chloro-2-(4-chloro-(((3,4-dichlorophenl)-carbamoyl)amino)phenoxy) benzene sulfonate hydrate). Interestingly, both of these chemicals produced binding curves with sharp drops in binding when tested in the Battelle Pacific Northwest Laboratories.
DISCUSSION
The purpose of the RUC ER-competitive binding assay is to identify chemicals that have the potential to compete with endogenous estrogens for binding to the ligand-binding domain of ER. The assay is conducted by measuring the binding of a single concentration of 3 H-17b-E 2 to RUC ER in the presence of increasing concentrations of radioinert E 2 or a test chemical. It is based upon the assumptions that (1) the radioligand and the test chemical compete for the same receptor site so that binding of one or the other is mutually exclusive (Fig. 1) , (2) the reaction is reversible and reaches equilibrium such that the rate of new ER ligand association equals the rate of dissociation, (3) neither the ligand nor ER is altered by binding. If these assumptions are met, the data can be analyzed using simple models based upon the law of mass action (Motulsky and Christopoulos, 2003) which predicts the fraction of receptors that will be occupied at equilibrium as a function of ligand concentration. Plotting the data as the percent 3 H-E 2 bound versus the concentration of radioinert E 2 or a test chemical produces a sigmoid curve with the top plateau equal to the maximal binding capacity in the absence of a competing ESTROGEN RECEPTOR-BINDING AFFINITY chemical and the bottom of the curve equal to the nonspecific binding. Theoretically, the maximal ER binding should drop from 100 to 0% over a 2-log increase in chemical concentration if the chemical is competing with 3 H-E 2 for a single receptor site. In addition, the slope factor (e.g., steepness of the binding curve, Hill slope) for a one-site competitive binding curve should be ÿ1.0. Chemicals that can inhibit binding at nanomolar concentrations have a higher affinity for ER compared with those that require micromolar or millimolar concentrations. Since the IC 50 is dependent upon the concentration of 3 H-E 2 used in the assay, the RBA (percent of test chemical IC 50 , compared with that of E 2 ) is commonly reported. Alternatively, another method for reporting binding affinity is to calculate a K i value (e.g., the concentration of the test chemical that will bind to one half of the ER in the absence of radioligand or other competitors) either by using the correction of Cheng and Prusoff (1973) to convert an IC 50 to K i or by determining a K i experimentally.
Here we report the K i values for 17 of 50 test chemicals that demonstrate true competitive binding for the ER. All produced full or partial competitive binding curves, and 16 of 17 chemicals inhibited at least 50% of the radioligand binding at concentrations up to 100lM. Further characterization of ER binding using Lineweaver-Burk double reciprocal plots and slope replots confirmed that these chemicals were true competitive inhibitors at the ER ligand-binding domain. K i concentrations for this group of chemicals ranged from 0.5 to 373lM. While all the competitors exhibited far less affinity for the ER than E 2 , the data support a conclusion that high concentrations could potentially act as ER agonists or antagonists. Since the RUC ER-competitive binding assays are limited to detecting the ability to interact with ER, additional tests, such as ER reporter gene assays, are needed to confirm agonist or antagonist activity, as well as the potential for in vivo activity.
The occurrence of nonsigmoid curves for some of the chemicals was not unexpected given the diversity in chemical structures and physical properties. Those curves that dropped dramatically over a single log unit change in the concentration clearly demonstrated the biochemical limitations of the RUC ER-competitive binding assay. Changes in the assay pH in the presence of high concentrations of test chemical can result in subtle to dramatic alterations in ER confirmation that would alter receptor-binding characteristics. What may initially appear as inhibition of binding can actually be an inability of ER to bind any ligand. In some cases, the chemical may totally denature the receptor. This was the case for ethanol when used in excess as a primary solvent for the test chemicals. In our experiments, we observed reduced binding capacity beginning at ethanol concentrations of 2%, while concentrations above 20% essentially destroyed all ER binding (data not shown).
Any chemical in excessive concentrations is likely to disrupt the biochemical stability of the assay and diminish the maximal binding of radiolabeled ligand. This is not a fundamental failure of in vitro binding assays but rather a requirement for optimal biochemical conditions to maintain receptor integrity at the ligand-binding domain. In addition, some chemicals may be capable of forming submicrometer aggregates that can then inhibit enzymatic and receptor proteins via a nonspecific mechanism that would not occur if individual molecules were present Ryan et al., 2003; Seidler et al., 2003) . Unfortunately, the limiting concentration will vary among the vast number of structurally diverse chemicals that may be screened in the RUC ER-competitive binding assay. Therefore, it is imperative that data which do not produce the expected sigmoid curve be viewed with circumspect until further evaluation. As expected, the K i experiments using the three chemicals that produced sudden drops in ER binding demonstrated that these chemicals were not true competitive inhibitors.
Chemical solubility was another issue reflected in the study results. Because the ER is physiologically active in aqueous intracellular fluid, the binding assays must also be conducted in aqueous buffers. Endogenous estrogens are highly nonpolar but can be suspended in aqueous buffers at biologically active concentrations. However, since the test chemicals typically have a much lower affinity for ER, there is a need to use concentrations of 1000-100,000 times that of E 2 in the assays. The overnight assay incubation at 4°C to achieve equilibrium of the reaction also exacerbates the solubility issue. In a review of in vitro ER-competitive binding assays, an expert panel recommended that chemicals be tested over the range of 1.0nM-1mM (ICCVAM, NICEATM, 2003b) . However, as demonstrated by the U-shaped and rapidly dropping curves observed in this study, a maximal concentration of 1mM will not be universally suitable for all chemicals. However, the use of a secondary K i experiment can facilitate the characterization of ER-binding activity for those chemicals that are soluble at concentrations at the IC 50 and for which a partial binding curve can be observed.
Chemical solubility issues rendered the competitive binding results inconclusive for 8 of 50 chemicals tested. These chemicals exhibited slight inhibition (21-49%) at concentrations up to 100lM, suggesting that they could be competitors at very high concentrations. This group poses a particularly vexing problem because, although a potential for ER binding was established, none of the chemicals were sufficiently soluble in the assay buffer system to permit a secondary analysis in a K i experiment. This points to a need to evaluate alternative solvents and approaches in order to properly evaluate these chemicals. Solubility issues will also likely be problematic for other in vitro assays, such as reporter gene assays, that might be employed to evaluate these chemicals.
The physiological relevance for testing chemicals up to 1.0mM concentrations is a question that still remains to be addressed before adopting the RUC ER-competitive binding assay as a routine screening tool. The present study demonstrates that the highest possible concentration for testing will 54 vary among the chemicals. Guidelines for maximal concentrations will need to consider the biochemical limitations of the RUC ER-competitive binding assay regarding the limit of solubility for each chemical, as well as any adverse effects a chemical may exert on the stability of the assay environment. In addition, testing a chemical at concentrations of 1,000,000-fold or greater than the K d for the ER enhances the risk of reaction with lower affinity binding sites of little or no physiological significance. Thus, safeguards to ensure that the assay is being conducted under proper biochemical conditions that will support the ligand binding to ER, as well as proper data interpretation, need to be employed in order to assess the binding characteristics of a given test chemical with accuracy. Setting an upper concentration limit for the assay will require a consensus on whether chemicals with K i values of 100lM or greater will pose a significant physiological risk to living organisms. Relative concentrations of xenoestrogens may vary substantially in vivo due to differences in bioaccumulation and/or the ability to bind to serum transport proteins (Bigsby et al., 1997; Nagel et al., 1997 Nagel et al., , 1998 . In addition, the dose that may be effective as an ER agonist or antagonist in vivo may or may not be directly correlated with the K i concentration (Zacharewski, 1997) .
In summary, true competitive inhibition of ER binding was observed for 17 of the 50 chemicals tested in this study. Albeit these chemicals reflected a very weak affinity for the ER, true competitive inhibition was observed even when the K i was as much as five orders of magnitude higher than that of E 2 . Importantly, 6% of the chemicals that appeared to be inhibitors in the competitive binding assay were in fact not true competitive inhibitors when further evaluated in the K i experiments. In addition, irregular, nonsigmoidal curves were observed for 8% of the chemicals. These chemicals may have altered the stability of the assay in some fashion, for example, by changing pH, denaturing ER, precipitating out of solution, or forming aggregates of individual molecules. This study demonstrates the importance of understanding the limitations of the RUC ER-competitive binding assay, as well as the proper interpretation of the data when testing chemicals over a broad range of structural and physiochemical diversity. While the competitive binding assay is itself a valuable tool for screening chemicals for potential estrogenic or antiestrogenic activity, the assay works best when supported by secondary analyses. Here, we used K i experiments to identify chemicals that were capable of true competitive binding to ER. Alternatively, other in vitro assays, such as an ER reporter gene or vitellogenin induction, might be employed to confirm estrogenic or antiestrogenic capability. Finally, these data show the range of results that can be obtained for a competitive binding assay when screening chemicals with diverse structural and physical properties. Although this study used RUC as the source for the ER, the issues discussed here are directly applicable to other assays utilizing alternative receptor sources, such as human recombinant ER or ER from other species, that might be more amenable to high throughput applications. By thoroughly evaluating the ER-binding characteristics using a double reciprocal Lineweaver-Burk model with a slope replot, our results demonstrated some potential errors that can occur during data interpretation. Such data are useful for the ongoing validation of the RUC ER-competitive binding assay as part of the EPA's EDSP, as well as to support research efforts to develop computational models to identify chemicals with the ability to bind to ER.
SUPPLEMENTAL DATA
Supplementary data are available online at http://toxsci. oxfordjournals.org/. Chemical structures and K i data will also be available for public access through the National Center for Computational Toxicology's Distributed Structure-Searchable Toxicity Database Network at http://www.epa.gov/ncct/dsstox/.
